The Interplay Between HIF‐1α and EZH2 in Lung Cancer and Dual‐Targeted Drug Therapy

The Interplay Between HIF‐1α and EZH2 in Lung Cancer and Dual‐Targeted Drug Therapy

Abstract Interactions between oncogenic proteins contribute to the phenotype and drug resistance. Here, EZH2 (enhancer of zest homolog 2) is identified as a crucial factor that mediates HIF‐1 (hypoxia‐inducible factor) inhibitor resistance. Mechanistically, targeting HIF‐1 enhanced the activity of E...

Full description

Bibliographic Details
Main Authors: Jianmin Wang, Cheng Yang, Huashen Xu, Xinyu Fan, Lina Jia, Yang Du, Shougeng Liu, Wenjing Wang, Jie Zhang, Yu Zhang, Xiaoxue Wang, Zhongbo Liu, Jie Bao, Songping Li, Jingyu Yang, Chunfu Wu, Jing Tang, Guoliang Chen, Lihui Wang
Format: Article
Language:English
Published: Wiley 2024-02-01
Series:Advanced Science
Subjects:
dual‐targeted drugs
feedback regulation
EZH2
HIF‐1α
lung cancer
Online Access:https://doi.org/10.1002/advs.202303904

Internet

https://doi.org/10.1002/advs.202303904

Similar Items